comprehensive -WSS

comprehensive

author：entertainment 2025-10-04 04:11:33 Page View：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dana Farber says 6 studies to be retracted and 31 corrected
Next article： Hollywood unions extend contract negotiations for actors

explore

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Biotech venture capitalists face new demands from investors

AdobeOverthelastyearortwo,somethingcurioushasstartedoccurringintheconferenceroomsandprivateZoommeeti

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Flu vaccine reformulation won't be easy, manufacturers warn

AdobeLastfall,theWorldHealthOrganizationandsomenationaldrugregulatorsurgedinfluenzavaccinemanufactur